tiprankstipranks
Company Announcements

Sareum Holdings Acquires Licence for SRA737, Strengthening Oncology Portfolio

Story Highlights
Sareum Holdings Acquires Licence for SRA737, Strengthening Oncology Portfolio

Sareum Holdings ( (GB:SAR) ) has provided an announcement.

Sareum Holdings has acquired the licence for SRA737, a clinical-stage oral Checkpoint kinase 1 inhibitor targeting cancer cell replication and DNA damage repair. This acquisition follows the programme’s return from a US-based biopharma company, with Sareum now securing a 63.5% share of future revenues. The move strengthens Sareum’s position to explore partnerships or development opportunities for SRA737, while ongoing costs will be limited to material and data storage, and intellectual property management. Sareum is also advancing its lead programme, SDC-1801, which has shown promising results in treating autoimmune diseases.

More about Sareum Holdings

Sareum Holdings PLC is a clinical-stage biotechnology company based in Cambridge, UK, focused on developing next-generation kinase inhibitors for autoimmune diseases and cancer.

YTD Price Performance: -32.65%

Average Trading Volume: 180,726

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £20.61M

Learn more about SAR stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App